Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study

Table 2 Unmet eligibility criteria with the worst grade in the ineligible group

Eligibility criteria	N (%)	Worst grade
Hemoglobin <10 g/dL	12 (35.3)	G2^a
Absolute neutrophil count <1500/mm³	11 (32.4)	G2^b
Platelets <10 × 10⁴/mm³	4 (11.8)	G2^c
Total bilirubin >1.5 x ULN	1 (2.9)	G2
AST or ALT >3 x ULN (5 x ULN in liver metastasis)	5 (14.7)	G3
Creatinine >2.0 mg/dL	0 (0.0)	–
Active infection	1 (2.9)	G2^d

Abbreviations: ULN, upper limit of normal; AST, aspartate aminotransferase; ALT, alanine aminotransferase; G, grade. No patient received interventions for decreased hemoglobin, absolute neutrophil count, or platelets
^aMean, 9.3 g/dL; range, 8.2–9.9 g/dL. The etiology of anemia was chemotherapy in 10 patients and cancer in 2 patients
^bMean, 1400/mm³; range, 1080–1470/mm³. Initial dose of eribulin was reduced in one patient
^cMean, 7.8 × 10⁴/mm³; range, 7.1–9.6 × 10⁴/mm³
^dInfection of cutaneous metastasis requiring an oral antibiotic. This patient also had hemoglobin <10 g/dL

ISSN: 1471-2407